Dr. Ming Yin, MD

Dr. Yin practices at Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center.

Dr. Yin's NPI, 1255630505, was assigned on March 24, 2011. Dr. Yin holds Ohio license 35.131033.

Dr. Yin's primary practice is Ohio State University Hospital, at 410 West 10th Avenue, Columbus, OH 43210 in Franklin County. The practice phone is (614) 293-9700.

Dr. Yin's primary practice is Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center. Dr. Yin is also affiliated with Tidelands Georgetown Memorial Hospital. The medical group on file is Tidelands Georgetown Memorial Hospital. Dmand AI also links Dr. Yin to 2 more hospitals, 5 group practices and clinics, 4 medical groups, 2 hospital outpatient departments and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yin practices, 12 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Yin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Yin is licensed in Ohio.

CMS data shows 1,068 Medicare services from Dr. Yin across 5 procedure codes in 2024, all of them office visits, for 235 Medicare patients. Medicare paid $93,327 for them. Every service was in an office.

CMS counts 235 Medicare patients who saw Dr. Yin in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yin's median patient age at 73, with 48% women.

In 2024, Dr. Yin wrote 657 Medicare Part D claims for 148 patients. 79% of them were for generic drugs. CMS names the drug for 393 of them, across 15 drugs with 11 or more claims each, at $558,279 in total drug cost. In 2023, CMS named 247 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Yin for performance year 2024, reported as part of a group. Dr. Yin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yin as offering telehealth.

Dmand AI links 52 papers to Dr. Yin, published from 2013 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Electrodes, Implanted. Dr. Yin has published most often in Annu Int Conf IEEE Eng Med Biol Soc. Dr. Yin's most frequent co-authors are Monika Joshi, MD, Joseph J. Drabick, MD and Edmund Folefac, MD.

Dmand AI links Dr. Yin to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Penile Neoplasms and Penile Diseases.

CMS Open Payments shows 89 general payments to Dr. Yin from 35 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 97% of the total. Merck Sharp & Dohme Corporation paid the most, $192.